Multiboost - MCC plus pertussis booster in adolescents

ISRCTN ISRCTN18766300
DOI https://doi.org/10.1186/ISRCTN18766300
EudraCT/CTIS number 2012-005273-31
Secondary identifying numbers 14867
Submission date
22/07/2013
Registration date
22/07/2013
Last edited
21/06/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Jo Southern
Scientific

Centre for Infections
Health Protection Agency
61 Colindale Avenue
London
NW9 5EQ
United Kingdom

Phone +44 20 7679 2000
Email jo.southern@phe.gov.uk

Study information

Study designRandomised interventional trial; Design type: Prevention, Treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typePrevention
Scientific titleA phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Meningitec™, or Menjugate™, or NeisVac-C™, or Menitorix™), when given concurrently with an acellular pertussis-containing booster vaccine (Repevax™ or IPV-Boostrix™)
Study objectivesThe aim of this study is to assess how well adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine is tolerated when given concurrently with an acellular pertussis-containing booster vaccine in adolescents aged between 14-17 years.
Ethics approval(s)13/LO/0681
Health condition(s) or problem(s) studiedTopic: Medicines for Children Research Network, Primary Care Research Network for England; Subtopic: All Diagnoses, Not Assigned; Disease: All Diseases
InterventionBoostriv-IPV, Combination dTaP3/IPV vaccine
Meningitec, Meningococcal serogroup C conjugate vaccine
Menitorix, Combined meningococcal serogroup C and Hib conjugate vaccine
Menjugate, Meningococcal serogroup C conjugate vaccine
NeisVac-C, Meningococcal serogroup C conjugate vaccine
Repevax, Combined dTaP5/IPV vaccine

Follow Up Length: 1 month

Study Entry : Single Randomisation only
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Meningitec, Menitorix, Menjugate, NeisVac-C, Repevax, Boostriv-IPV
Primary outcome measureMeningococcal serogroup C-specific and pertussis-specific immune response
Secondary outcome measures1. Safety and tolerability of each study combination of MCC and pertussis-containing vaccine
2. Tetanus, diphtheria, and (in appropriate study arms) Hib immune response
Overall study start date12/08/2013
Completion date12/03/2015

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsPlanned Sample Size: 880; UK Sample Size: 880; Description: 110 participants per group, over 8 groups = 880 total. To account for attrition we will use a +/10% tolerance around these figures
Total final enrolment388
Key inclusion criteria1. Participant is willing and able to give written informed consent for participation. If aged below 16 years, parent/legal guardian gives consent while the participant gives written assent for participation in the study.
•2. Male or female aged 14 years (+0 day) to 17 years (+364 days) on the day of consent.
•3. Completed MCC and pertussis vaccination according to the UK (catch-up and/or routine) schedule appropriate for the participant’s age
Key exclusion criteriaExclusion Criteria
The participant may not enter the study if ANY of the following apply:
•1. Any contraindication to vaccination as specified in the “Green Book”- Immunisation against Infectious Disease, HMSO.
•2. Significant illness including progressive neurological disease or seizure disorder; confirmed or suspected immunosuppressive or immunodeficient conditions; major congenital defects; or known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time).
•3. Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
4. History of invasive meningococcal disease or pertussis.
5. Significant contact (household or intimate exposure) to an individual with culture proven Neisseria meningitis disease or pertussis in the previous 60 days.
6. Any MCC or pertussis vaccination that is not according to the UK (catch-up or routine) schedule appropriate for the participant’s age.
7. Pregnancy

Temporary Exclusion Criteria
1. Fever (sublingual temperature >= 38°C)
2. Received systemic antibiotic(s) (either oral or parenteral) within the past 7 days. For all visits, if allowed by the study visit window, receipt of systemic antibiotics (either oral or parenteral) will delay venepuncture until at least 7 days after cessation of antibiotics.
3. Received any blood or blood products within the past 12 weeks.
4. Received another investigational agent within 90 days - or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial to the end of this study.
5. Possibility of pregnancy: All female potential participants will be assessed for the possibility of being pregnant. Assessment will be in accordance with SOP CTSOP071 (Pregnancy Testing and Exclusion from Studies). If there is a possibility of being pregnant, they will be advised to consult their own GP for a pregnancy test. They can only be considered for recruitment if they choose to take a test and are negative.
Date of first enrolment12/08/2013
Date of final enrolment12/03/2015

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Centre for Infections
London
NW9 5EQ
United Kingdom

Sponsor information

Health Protection Agency (HPA)
Government

Centre for Infections
61 Colindale Avenue
London
NW9 5EQ
United Kingdom

Website http://www.hpa.org.uk/
ROR logo "ROR" https://ror.org/03sbpja79

Funders

Funder type

Government

Department of Health - Policy Research Programme

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 21/06/2019 No No
HRA research summary 28/06/2023 No No

Editorial Notes

21/06/2019: Added clinicaltrialsregister.eu link to basic results (scientific). Added total final enrollment.
17/01/2017: No publications found in PubMed, verifying study status with principal investigator.